3rd Quarter 2025 Results

3rd Quarter 2025 Sales

$24.0B Worldwide increased ▲ **6.8%**

Excluding the impact of translational currency
Stelara impacted results by ~(640) basis points
Worldwide increased ▲ **5.4%**[1]


Diluted earnings per share (EPS)

$2.12 Worldwide increased ▲ **91.0%**

Adjusted diluted earnings per share[1]

$2.80 Worldwide increased ▲ **15.7%**





Joaquin Duato
Chairman & Chief Executive Officer
Johnson & Johnson

"Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline. With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson & Johnson is in a new era of accelerated growth and innovation, with pioneering treatments that will continue to transform lives."

$15.6 billion Worldwide Innovative Medicine sales

Innovative Medicine worldwide reported sales increased 6.8% or 5.3% operationally[2]. Stelara impacted results[2] by ~(1,070) basis points. Primary operational drivers:

DARZALEX (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL
Tremfya (guselkumab)
CAPLYTA (lumateperone) capsules 42 mg
CARVYKTI (ciltacabtagene autoleucel) Suspension for IV Infusion
Spravato (esketamine) CIII nasal spray
Simponi (golimumab)
Erleada (apalutamide) 60 mg tablets 240 mg tablet
RYBREVANT (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE (lazertinib)

$8.4 billion Worldwide MedTech sales

MedTech worldwide reported sales increased 6.8% or 5.6% operationally[2] Primary operational drivers:

- Electrophysiology
- Abiomed
- Wound Closure
- Shockwave
- Surgical Vision
- Biosurgery
- Contact Lenses

For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson's earnings release issued on October 14, 2025 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx
[1] Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.
[2] Non-GAAP measure; excludes the impact of translational currency.
Note: Values may be rounded
Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on October 14, 2025 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson&Johnson